Biotech Values

[fid]

"The Phase II trial FAILED."
The Phase II did not fail.

- The 250 mg dose of MC-1 had a 14.0% reduction in the primary endpoint composite of death, non-fatal myocardial infarction (peak CK-MB greater than or equal to 50ng/ml), and non-fatal stroke versus placebo (p equals 0.312).


"The Phase II trial showed no change in MORTALITY."
A drug is not going to improve on some mechanical problems.

Your an anestheist, yah okay.

"The current trial will likely also show no benefit in MORTALITY."
The current trial is not designed to show a mortality benefit.

Happy investing